gemifloxacin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 1286 175463-14-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gemifloxacin mesilate
  • gemifloxacin
  • gemifloxacin mesylate
A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.
  • Molecular weight: 389.39
  • Formula: C18H20FN5O4
  • CLOGP: -1.25
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 121.35
  • ALOGS: -3.27
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.32 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 3.52 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.30 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 27, 2002 Korean Food and Drug Administration (KFDA)
April 4, 2003 FDA LG LIFE SCIENCES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 12.94 0 3 4 46640 2311438

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC J01MA15 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
FDA EPC N0000175937 Quinolone Antimicrobial
FDA CS M0023650 Quinolones
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:36047 antibacterial drug
MeSH PA D059005 Topoisomerase II Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Bacterial pneumonia indication 53084003 DOID:874
Pneumonia due to Klebsiella pneumoniae indication 64479007
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial bronchitis indication 233598009
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Acute exacerbation of chronic bronchitis indication 425748003
Moraxella Catarrhalis Pneumonia indication
Torsades de pointes contraindication 31722008
Transplantation of heart contraindication 32413006
Tendinitis contraindication 34840004 DOID:971
Depressive disorder contraindication 35489007
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Transplant of kidney contraindication 70536003
Epilepsy contraindication 84757009 DOID:1826
Transplant of lung contraindication 88039007
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Impaired renal function disorder contraindication 197663003
Peripheral nerve disease contraindication 302226006
Pseudomembranous enterocolitis contraindication 397683000
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.27 acidic
pKa2 9.75 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 4 subunit A Enzyme INHIBITOR WOMBAT-PK CHEMBL
DNA gyrase subunit B Enzyme WOMBAT-PK
DNA topoisomerase 4 subunit A Enzyme IC50 6.52 CHEMBL

External reference:

IDSource
D000077735 MESH_DESCRIPTOR_UI
4021386 VUID
N0000148804 NUI
C0533545 UMLSCUI
D02471 KEGG_DRUG
407087003 SNOMEDCT_US
407086007 SNOMEDCT_US
000543 NDDF
138099 RXNORM
d04859 MMSL
4021386 VANDF
CHEMBL430 ChEMBL_ID
CHEMBL1200621 ChEMBL_ID
OKR68Y0E4T UNII
7877 INN_ID
DB01155 DRUGBANK_ID
CHEBI:101853 CHEBI
210353-53-0 SECONDARY_CAS_RN
9571107 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
FACTIVE HUMAN PRESCRIPTION DRUG LABEL 1 44001-321 TABLET 320 mg ORAL NDA 18 sections
FACTIVE HUMAN PRESCRIPTION DRUG LABEL 1 44004-321 TABLET 320 mg ORAL NDA 18 sections